John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Therapeutic management of grade 1-2 metastatic neuroendocrine tumors in 2016 Volume 23, supplement 2, Octobre 2016

Figures

  • Figure 1

Tables

Authors
1 Hôpital Cochin, service de gastro-entérologie et oncologie digestive, Université Paris Descartes, Sorbonne Paris Cité, 27 rue du Faubourg Saint Jacques, 75014 Paris, France
2 Unité INSERM U1016
* Tirés à part

Gastro-entero-pancreatic neuroendocrine tumors (GEP NETs) are complexes and heterogeneous neoplasms whose management requires a multidisciplinary approach, depending of primary location, tumoral aggressiveness (Ki-67 grade, differentiation) and metastatic pattern. Several new options are available for the past decade for digestive metastatic G1-G2 NETs, reinforcing the therapeutic arsenal: somatostatin analogues (long acting form of lanreotide and octreotide), targeted drugs (everolimus and sunitinib) and more recently the 177-Lu octreotate peptide radionuclide receptor therapy. These latter are added to older treatments such as systemic chemotherapy, interferon, and hepatic transarterial treatments. Considering those options, the 2016 ENETS (European NeuroEndocrine Tumor Society) guidelines have been recently published to clarify the therapeutic strategy and guide clinicians, even if, in some situations no consensus exists. In the present review we detail the available options in G1-G2 metastatic GEP NET.